PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
Disclosed herein is a vaccine comprising an antigen and PD1 antibody and/or PDL1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.
1. A composition for enhancing a T-cell response against an antigen in a subject in need thereof, comprising:
a) programmed cell death protein ligand 1 (PDL1) monoclonal antibody, and
b) a nucleic acid molecule comprising nucleic acid sequence encoding a synthetic consensus HPV16 antigen capable of generating an immune response against HPV16 in the subject, or an immunogenic fragment or variant thereof.
2. The composition of claim 1 wherein the nucleic acid molecule is an isolated DNA that encodes for the antigen.
3. The composition of claim 1 , wherein the PD1 antibody and PDL1 antibody is selected from the group consisting of: nivolumab, pembrolizumab, pidilizumab, BMS-936559, MPDL3280A, MDX1105-01, MEDI4736, and MK-3475.
4. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
5. A method for inducing an immune response in a subject in need thereof, the method comprising administering a therapeutically effective dose of the composition of claim 1 to the subject.
6. The method of claim 5 , wherein administering the composition comprises an electroporating step.